- Home
- NWN vs DAWN Comparison
NWN vs DAWN Comparison
Compare NWN & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWN
- DAWN
- Stock Information
- Founded
- NWN 1859
- DAWN 2018
- Country
- NWN United States
- DAWN United States
- Employees
- NWN N/A
- DAWN N/A
- Industry
- NWN Oil/Gas Transmission
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- NWN Utilities
- DAWN Health Care
- Exchange
- NWN Nasdaq
- DAWN Nasdaq
- Market Cap
- NWN 1.5B
- DAWN 1.6B
- IPO Year
- NWN N/A
- DAWN 2021
- Fundamental
- Price
- NWN $41.14
- DAWN $13.31
- Analyst Decision
- NWN Strong Buy
- DAWN Strong Buy
- Analyst Count
- NWN 2
- DAWN 7
- Target Price
- NWN $43.50
- DAWN $36.17
- AVG Volume (30 Days)
- NWN 228.6K
- DAWN 1.3M
- Earning Date
- NWN 11-12-2024
- DAWN 10-30-2024
- Dividend Yield
- NWN 4.76%
- DAWN N/A
- EPS Growth
- NWN N/A
- DAWN N/A
- EPS
- NWN 2.06
- DAWN N/A
- Revenue
- NWN $1,137,832,000.00
- DAWN $101,953,000.00
- Revenue This Year
- NWN N/A
- DAWN N/A
- Revenue Next Year
- NWN $3.62
- DAWN $44.21
- P/E Ratio
- NWN $19.98
- DAWN N/A
- Revenue Growth
- NWN N/A
- DAWN N/A
- 52 Week Low
- NWN $34.82
- DAWN $11.30
- 52 Week High
- NWN $42.56
- DAWN $18.07
- Technical
- Relative Strength Index (RSI)
- NWN 56.55
- DAWN 35.44
- Support Level
- NWN $40.38
- DAWN $14.30
- Resistance Level
- NWN $42.56
- DAWN $15.92
- Average True Range (ATR)
- NWN 0.92
- DAWN 0.90
- MACD
- NWN 0.14
- DAWN -0.17
- Stochastic Oscillator
- NWN 68.65
- DAWN 0.29
About NWN Northwest Natural Holding Company
Northwest Natural Holding Co is a public natural gas service supplier operating in the U.S. Pacific Northwest. Its subsidiary, NW Natural, operates through the natural gas distribution segment, which purchases and distributes natural gas through which operates in Oregon and southwest Washington. The company generates its revenue from residential, commercial, and industrial customers, the majority of which are in Oregon. Residential and commercial customers account for the vast majority of profitability.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.